The field of cellular therapy has become increasingly complicated in all aspects, including technical, patient, environment, and regulatory. For example, the logistics of apheresis collection as well as the utilization of fresh stem cell product have changed significantly during the current COVID-19 pandemic. In this session, different logistical solutions that apheresis collection facilities have used during the pandemic will be discussed. New regulatory requirements introduced during the COVID-19 pandemic will be reviewed (e.g new FDA guidance) and how these can be implemented into routine operations will be discussed.
To view Spanish or English subtitles, click the "CC" box in the video player. Para ver subtítulos en español o inglés, haga clic en el cuadro "CC" en el reproductor de video.
Summarize different logistical modifications apheresis collection facilities adapted during the COVID-19 pandemic
Discuss different logistical modifications transplant centers have adapted during the COVID-19 pandemic
Review updated regulatory cellular therapy requirements during the COVID-19 pandemic and their effect on collection of cells for further manufacturing
All relevant financial relationships have been mitigated. By completing the evaluation, you are attesting to watching the presentation in its entirety. A certificate will be immediately provided after submission.
AM21-03: Challenges in Apheresis Cellular Collections during the COVID-19 Pandemic Evaluation